Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 Biomarker disease BEFREE This study demonstrates that clinically relevant doses of venlafaxine extended-release block the norepinephrine transporter of the major depressive disorder patient's brain. 30649319 2019
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 GeneticVariation disease BEFREE In conclusion, NET gene rs5569 polymorphism could increase the risk of MDD, especially among Asians. 30292339 2018
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 GeneticVariation disease BEFREE Association between T-182C, G1287A polymorphism in NET gene and suicidality in major depressive disorder in Chinese patients. 29703117 2018
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 Biomarker disease BEFREE NET impairment is evident in several clinically important conditions including major depressive disorder (MDD), panic disorder (PD), essential hypertension and the postural orthostatic tachycardia syndrome (POTS). 27046647 2017
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 GeneticVariation disease BEFREE NET rs2242446/T-182C may serve as a biomarker to predict the likelihood of remission with venlafaxine in older adults with major depression. 28068779 2017
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 Biomarker disease BEFREE The authors tested norepinephrine transporter availability in patients with major depressive disorder with the aim to identify any associations between test results and clinical symptoms. 27631962 2017
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 GeneticVariation disease BEFREE We investigated the relationship between the brain volume and these two polymorphisms of the SLC6A2 in MDD patients. 26960194 2016
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 GeneticVariation disease BEFREE We conducted an 8-week, open-label, prospective pilot study in 35 patients with major depressive disorder to assess the effects of genetic variations in SLC6A2 and SLC6A4 on both efficacy and side effect profile of desvenlafaxine. 27023264 2016
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 GeneticVariation disease BEFREE This study attempted to examine the relationship between polymorphisms of NET gene and MD. 26061302 2015
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 GeneticVariation disease BEFREE The aim of this study was to examine whether polymorphisms in the norepinephrine transporter gene (SLC6A2) associate with remission after venlafaxine treatment for MDD. 25512257 2015
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 GeneticVariation disease BEFREE We investigated the separate effects and possible interactions between NET T-182C (rs2242446) and SERT 5-HTTLPR (rs4795541) polymorphisms on selective serotonin reuptake inhibitors (SSRI) treatment response and temperamental traits assessed by the Temperament and Character Inventory (TCI) in a clinical sample of subjects with major depressive disorder (MDD). 25739526 2015
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 GeneticVariation disease BEFREE Our study aimed to investigate the solute carrier family 6 (neurotransmitter transporter and serotonin) member 4 (SLC6A4) gene locus, encoding 5-HTT and SSRI treatment response in late-life MDD. 25827644 2015
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 GeneticVariation disease BEFREE Serotonin transporter (5-HTTLPR) and norepinephrine transporter (NET182C) polymorphisms are associated with susceptibility and treatment response in major depressive disorder (MDD). 25650523 2015
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 Biomarker disease PSYGENET This study attempted to examine the relationship between polymorphisms of NET gene and MD. 26061302 2015
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 Biomarker disease BEFREE A total of 26 outpatients with treatment-resistant MDD and 27 matched healthy controls underwent magnetic resonance imaging and genotyping for six SNPs in monoaminergic genes [serotonin transporter (SLC6A4), norepinephrine transporter (SLC6A2), serotonin 1A and 2A receptors (HTR1A and HTR2A), catechol-O-methyltransferase (COMT), and brain-derived neurotrophic factor (BDNF)]. 25990886 2015
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 Biomarker disease PSYGENET Serotonin transporter (5-HTTLPR) and norepinephrine transporter (NET182C) polymorphisms are associated with susceptibility and treatment response in major depressive disorder (MDD). 25650523 2015
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 Biomarker disease PSYGENET The aim of this study was to examine whether polymorphisms in the norepinephrine transporter gene (SLC6A2) associate with remission after venlafaxine treatment for MDD. 25512257 2015
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 GeneticVariation disease BEFREE Conclusively, the present meta-analysis did not suggest a confirmed association between the T-182C polymorphism of the NET gene and MDD. 24374057 2014
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 GeneticVariation disease BEFREE There were no relationships between lethality scores and SLC6A2 polymorphisms in suicidal MDD. 24655776 2014
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 Biomarker disease PSYGENET There were no relationships between lethality scores and SLC6A2 polymorphisms in suicidal MDD. 24655776 2014
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 PosttranslationalModification disease BEFREE The objective of this study was to characterise the DNA methylation state of the SLC6a2 gene promoter in patients with MDD and panic disorder. 24312678 2013
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 Biomarker disease PSYGENET Patients with MDD or panic disorder were not found to differ significantly from healthy controls in the pattern of methylation of the SLC6a2 gene promotor. 24312678 2013
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 GeneticVariation disease BEFREE Our findings suggest that the NET T-182C and G1287A polymorphisms are not susceptibility factors for MDD. 23648227 2013
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 GeneticVariation disease BEFREE In self-identified white patients with major depressive disorder (N=126) treated with open-label duloxetine (60-120 mg/d), a significant association of (P=0.020) of a composite risk score (based on SLC6A2 rs5569 [G1287A] AA, HTR1A rs6295 [C(-1019)G] GG, and COMT rs174697 AA/AG) with 17-item Hamilton Depression Rating Scale total score change from baseline to 12 weeks was observed. 22727709 2012
Entrez Id: 6530
Gene Symbol: SLC6A2
SLC6A2
0.400 GeneticVariation disease BEFREE 252 unrelated Caucasian patients (f = 142; m = 110) with major depression were genotyped for NET and 5-HTT polymorphisms. 20588071 2010